The price at which the company is being sold is 97% lower than the price at which trading in the share began in 2007.
Global life science investment group Ally Bridge Group has invested $70 million in two Israeli companies.
The Rehovot-based company is leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies.
The Israel Innovation Authority has granted GE NIS 50 million to expand its Rehovot center.
A court ordered Teva to restore the Copaxone rights for treatment of diseases other than multiple sclerosis to Proneuron, but the patent has expired, rendering the rights useless.
However, Berkshire Hathaway still has a loss on paper on its investment in Teva of about $230 million.
Eli Kalif tells "Globes" that growth will be enhanced by streamlining factories rather than more closures and selloffs.
The Israeli pharmaceutical company sees higher revenue and profit in 2020.
Ichilov Hospital CEO Ronni Gamzu is furious about Benny Gantz's populist comments and says that education and transport have bigger problems than the health services.
Ben Gurion University researcher Dr. Tomer Hertz says flu jabs, like vaccinations against childhood diseases, are a social act that helps prevent infecting others.